Prevention of restenosis: Is angioplasty the answer?

Heart

Volumn 93, Issue 5, 2007, Pages 539-541

  Scheller, Bruno ^a   Speck, Ulrich ^b   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PACLITAXEL;

ANGIOGRAPHY; ANGIOPLASTY; DRUG ELUTING STENT; EDITORIAL; HUMAN; PRIORITY JOURNAL; RESTENOSIS; THROMBOSIS; DRUG IMPLANT; METHODOLOGY; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; DRUG IMPLANTS; HUMANS; STENTS;

EID: 34247857481     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.118059     Document Type: Editorial

References (28)

1. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis. Fact, fancy and future. Circulation 1994;90:2070-82.
2. Kuntz RE, Baim DS. Prevention of coronary restenosis: the evolving evidence base for radiation therapy. Circulation 2000;101:2130-3.
3. Waksman R. Late thrombosis after radiation. Sitting on a time bomb. Circulation 1999;100:780-2.
4. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
5. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-95.
6. Fattori R, Tommaso P. Drug-eluting stents in vascular intervention. Lancet 2003;361:247-49.
7. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
8. Pfisterer M, Brunner-La Rocca HP, Buser PT, BASKET-LATE Investigators, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91.
9. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61.
10. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis, Eur Heart J 2006;27:2784-814.
11. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001;104:600-5.
12. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
13. Iofina E, Langenberg R, Blindt R, et al. Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions. Am J Cardiol 2006;98:1022-7.
14. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
15. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-7.
16. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
17. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
18. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000;35:1969-96.
19. Hou D, Rogers PI, Toleikis PM, et al. Intrapericardial paclitaxel delivery inhibits neointimal proliferation and promotes arterial enlargement after porcine coronary overstretch. Circulation 2000;102:1575-81.
20. Mori T, Kinoshita Y, Watanabe A, et al. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol 2006;58:665-72.
21. Scheller B, Speck U, Romeike B, et al. Contrast media as a carrier for local drug delivery: successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 2003;24:1462-7.
22. Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 2003;42:1415-20.
23. Scheller B, Speck U, Abramiuk C, et al. Paclitaxel balloon coating - a novel method for prevention and therapy of restenosis. Circulation 2004;110:810-4.
24. Speck U, Scheller B, Abramjuk C, et al. Restenosis inhibition by non-stent-based local drug delivery: comparison of efficacy to a drug eluting stent in the porcine coronary overstretch model. Radiology 2006;240:411-8.
25. Kipshidze N, Dangas G, Tsapenko M, et al. Role of endothelium in modulating neointimal formation. Vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 2004;44:733-9.
26. Friedrich EB, Walenta K, Scharlau J, et al. CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 2006;98:e20-5.
27. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of in-stent restenosis with a paclitaxel-coated balloon catheter. New Engl J Med 2006;355:2113-24.
28. Kastrati A, Mehilli J, von Beckerath N, ISAR-DESIRE Study Investigators, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71.